ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data
Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000, has completed enrolment and is ongoing
- Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000, has completed enrolment and is ongoing
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to provide detailed pre-clinical, clinical and pharmacokinetic data from the Phase 1a dose escalation study of its lead pre|CISIONTM programme, AVA6000, a tumour activated form of doxorubicin. - The key conclusions drawn from the data for AVA6000 to date are:
The pre|CISIONTM platform targets the release of a chemotherapy to the tumour as intended. - A maximum tolerated dose has not been reached in the three-weekly dose escalation study despite dosing approximately 3.5x the normal level of doxorubicin in the highest and final dose cohort in this part of the Phase 1a study.
- Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.